Publications by authors named "E Koller"
Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. However, predictors of outcome are elusive. The objective of the current retrospective observational multicenter study of 240 adult patients (median age 68.
View Article and Find Full Text PDFArticle Synopsis
- * Antifungal prophylaxis has reduced IFD occurrences but has also changed the types of fungal pathogens seen, necessitating broader screening methods for early diagnosis and treatment.
- * A study analyzed blood samples from high-risk patients using advanced PCR techniques, revealing that many detectable fungi were typically non-pathogenic, highlighting the need for repeated testing and accurate identification to guide effective treatment.
Article Synopsis
- Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are serious blood cancers that involve the rapid increase of abnormal white blood cells, and recent research has highlighted BRD4 and MYC as potential targets for new drug therapies.
- In experiments comparing various BRD4-targeting drugs, including the BET inhibitor JQ1 and BRD4 degraders dBET1 and dBET6, all three were effective at reducing the growth of AML and ALL cells, including resistant leukemic stem cells.
- Notably, dBET6 outperformed the others by overcoming drug resistance, showing especially promising results when paired with other medications, and it also inhibited the expression of the resistance-related PD-L1 antigen in
The tetracycline transactivator (tTA) system provides controllable transgene expression through oral administration of the broad-spectrum antibiotic doxycycline. Antibiotic treatment for transgene control in mouse models of disease might have undesirable systemic effects resulting from changes in the gut microbiome. Here we assessed the impact of doxycycline on gut microbiome diversity in a tTA-controlled model of Alzheimer's disease and then examined neuroimmune effects of these microbiome alterations following acute LPS challenge.
View Article and Find Full Text PDFAntisense-oligonucleotides (ASOs) are a promising drug modality for the treatment of neurological disorders, but the currently established route of administration intrathecal delivery is a major limitation to its broader clinical application. An attractive alternative is the conjugation of the ASO to an antibody that facilitates access to the central nervous system (CNS) after peripheral application and target engagement at the blood-brain barrier, followed by transcytosis. Here, we show that the diligent conjugate design of Brainshuttle-ASO conjugates is the key to generating promising delivery vehicles and thereby establishing design principles to create optimized molecules with drug-like properties.
View Article and Find Full Text PDF